Gufic Biosciences · NSE: GUFICBIO · BSE: 509079
Q4 FY23 results · Jan–Mar 2023
Gufic Biosciences reported revenue from operations of ₹173.04 crore (up 6.7% from Q4 FY22) and net profit of ₹18.11 crore (down 10.7% from Q4 FY22) for Q4 FY23 (Jan–Mar 2023), on a standalone basis.
| Item | Q4 FY23 | Q4 FY22 | YoY | Q3 FY23 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 173.04 | 162.19 | +6.7% | 177.47 | −2.5% |
| Other income | 0.62 | 0.04 | 15x | 0.76 | −17.7% |
| Total income | 173.66 | 162.23 | +7.0% | 178.23 | −2.6% |
| Profit before tax | 23.93 | 26.18 | −8.6% | 27.25 | −12.2% |
| Net profit for the period | 18.11 | 20.26 | −10.7% | 20.34 | −11.0% |
| EPS, basic (₹) | 1.87 | 2.09 | −10.5% | 2.10 | −11.0% |
| Net margin (%) | 10.5 | 12.5 | 11.5 |
Standalone
- Filed with BSE
- 29 May 2023, 20:54 IST
- Board meeting
- 29 May 2023
- Period
- 01 Jan 2023 to 31 Mar 2023
- Review status
- Audited
- Source
- XBRL filing on BSE